OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
Eligibility Criteria
Patient Population
IgA Nephropathy
About the Drug
What is involved for the patient
Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.
Sponsor
Omeros Corporation
Target Enrollment
430
Estimated End Date
April 2023
About the Trial
Study Drug
OMS721
Study Goal
To determine if OMS721 reduces proteinuria in patients with IgAN.
About the drug or intervention
MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system.